BDX
SIX:BDX
BD
- Stock
169.54
−18.13%
−15.78
news - 4 hours ago
BD Announces First Pharma-Sponsored Clinical Trial Using Its Wearable injector Technology for Biologics
BD, a healthcare company, announced the initiation of its first pharma-sponsored clinical trial utilizing its wearable injector technology for biologics.
healthcarepackaging.comnews - 7 hours ago
Drug Delivery Infusion System Market Accelerates with Next-Gen & Wireless Trends, Projected to...
The global drug delivery infusion system market is projected to reach US$22.62 billion by 2033, growing at a 6.8% CAGR. Key drivers include advancements in MRI-compatible pumps, precision therapy solutions, and expanded use in oncology, homecare, and telehealth. Major players like Medtronic, Eitan Medical, and ICU Medical have received FDA clearances for innovative devices, while regions like Japan and the U.S. lead in adoption due to aging populations and healthcare infrastructure.
openpr.comnews - 19 hours ago
Global Cell Analyzer Market forecast to grow at 8% CAGR driven by lab automation and tech growth by 2030
The global cell analyzer market is projected to grow at a 8% CAGR from 2025 to 2030, driven by advancements in cell analysis technologies, rising demand for single-cell analysis, and automation in research and clinical applications. Key applications include drug discovery, immunology, oncology, and regenerative medicine, with major players like Becton Dickinson and Thermo Fisher Scientific leading the industry.
pharmiweb.comnews - Jul 27, 2025 - 08:26
Becton, Dickinson and Company (NYSE:BDX) Receives Average Recommendation of “Hold” from Brokerages
Becton, Dickinson and Company (BDX) received an average 'Hold' rating from 11 brokerages, with 7 analysts rating it 'Hold' and 4 'Buy'. The average 1-year target price is $219.22. Analysts including Raymond James, Wells Fargo, and Goldman Sachs downgraded the stock. The company reported $3.35 EPS, exceeding estimates, with $5.27B revenue. Insiders sold shares, and institutional investors increased positions. The company declared a $1.04 quarterly dividend.
defenseworld.netnews - Jul 26, 2025 - 22:58
BD announces wearable injector trial for subcutaneous delivery of biologics
BD announced a trial using the BD Libertas wearable injector for subcutaneous delivery of biologics, following positive results from over 50 pre-clinical and clinical studies. The device features a transparent window, push-button activation, and color-coded status indicators, and is not subject to FDA 510(k) or EU CE mark certification, enabling faster commercialization. BD is validating fill-finish processes with contract manufacturers to support pharmaceutical collaborators.
finance.yahoo.comDescription
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral ca...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus